A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
NCT07219420
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Palmoplantar Pustulosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- UCB Biopharma SRL
- Last updated on ClinicalTrials.gov
- August 27, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- Ppp001 50754 · Birmingham, AL
California · 1
- Ppp001 50176 · Fremont, CA
Florida · 1
- Ppp001 50746 · Miami, FL
Michigan · 1
- Ppp001 50757 · Auburn Hills, MI
Ohio · 3
- Ppp001 50745 · Columbus, OH
- Ppp001 50202 · Fairborn, OH
- Ppp001 50733 · Mayfield Heights, OH
Oklahoma · 1
- Ppp001 50744 · Oklahoma City, OK
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.